164 related articles for article (PubMed ID: 32985018)
1. CD44
Wróbel T; Luty M; Catapano J; Karnas E; Szczygieł M; Piwowarczyk K; Ryszawy D; Drabik G; Zuba-Surma E; Siedlar M; Madeja Z; Elas M; Czyż J
Stem Cells; 2020 Sep; 38(12):1544-56. PubMed ID: 32985018
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Fenofibrate Treatment Stimulates the Phenotypic Microevolution of Prostate Cancer Cells In Vitro.
Warzecha KW; Pudełek M; Catapano J; Madeja Z; Czyż J
Pharmaceuticals (Basel); 2022 Oct; 15(11):. PubMed ID: 36355492
[TBL] [Abstract][Full Text] [Related]
3. Fenofibrate Augments the Sensitivity of Drug-Resistant Prostate Cancer Cells to Docetaxel.
Luty M; Piwowarczyk K; Łabędź-Masłowska A; Wróbel T; Szczygieł M; Catapano J; Drabik G; Ryszawy D; Kędracka-Krok S; Madeja Z; Siedlar M; Elas M; Czyż J
Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30641904
[TBL] [Abstract][Full Text] [Related]
4. Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Catapano J; Luty M; Wróbel T; Pudełek M; Piwowarczyk K; Kędracka-Krok S; Siedlar M; Madeja Z; Czyż J
Cell Mol Biol Lett; 2022 Nov; 27(1):100. PubMed ID: 36401206
[TBL] [Abstract][Full Text] [Related]
5. The stem cell inhibitor salinomycin decreases colony formation potential and tumor-initiating population in docetaxel-sensitive and docetaxel-resistant prostate cancer cells.
Gruber M; Handle F; Culig Z
Prostate; 2020 Feb; 80(3):267-273. PubMed ID: 31834633
[TBL] [Abstract][Full Text] [Related]
6. Enrichment of prostate cancer stem-like cells from human prostate cancer cell lines by culture in serum-free medium and chemoradiotherapy.
Wang L; Huang X; Zheng X; Wang X; Li S; Zhang L; Yang Z; Xia Z
Int J Biol Sci; 2013; 9(5):472-9. PubMed ID: 23781140
[TBL] [Abstract][Full Text] [Related]
7. Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial-mesenchymal Transition in Aggressive Variant Prostate Cancers.
Mitra Ghosh T; Mazumder S; Davis J; Yadav J; Akinpelu A; Alnaim A; Kumar H; Waliagha R; Church Bird AE; Rais-Bahrami S; Bird RC; Mistriotis P; Mishra A; Yates CC; Mitra AK; Arnold RD
Cancer Res Commun; 2023 Jul; 3(7):1286-1311. PubMed ID: 37476073
[TBL] [Abstract][Full Text] [Related]
8. Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration-resistant prostate cancer.
Keresztes D; Csizmarik A; Nagy N; Módos O; Fazekas T; Bracht T; Sitek B; Witzke K; Puhr M; Sevcenco S; Kramer G; Shariat S; Küronya Z; Takács L; Tornyi I; Lázár J; Hadaschik B; Lászik A; Szűcs M; Nyirády P; Szarvas T
J Cell Mol Med; 2022 Feb; 26(4):1332-1337. PubMed ID: 34970839
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells.
Mimeault M; Johansson SL; Henichart JP; Depreux P; Batra SK
Mol Cancer Ther; 2010 Mar; 9(3):617-30. PubMed ID: 20179163
[TBL] [Abstract][Full Text] [Related]
10. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer.
Marín-Aguilera M; Codony-Servat J; Reig Ò; Lozano JJ; Fernández PL; Pereira MV; Jiménez N; Donovan M; Puig P; Mengual L; Bermudo R; Font A; Gallardo E; Ribal MJ; Alcaraz A; Gascón P; Mellado B
Mol Cancer Ther; 2014 May; 13(5):1270-84. PubMed ID: 24659820
[TBL] [Abstract][Full Text] [Related]
11. CD44v8-10 mRNA contained in serum exosomes as a diagnostic marker for docetaxel resistance in prostate cancer patients.
Kato T; Mizutani K; Kawakami K; Fujita Y; Ehara H; Ito M
Heliyon; 2020 Jul; 6(7):e04138. PubMed ID: 32642575
[TBL] [Abstract][Full Text] [Related]
12. Midkine silencing enhances the anti-prostate cancer stem cell activity of the flavone apigenin: cooperation on signaling pathways regulated by ERK, p38, PTEN, PARP, and NF-κB.
Erdogan S; Turkekul K; Dibirdik I; Doganlar ZB; Doganlar O; Bilir A
Invest New Drugs; 2020 Apr; 38(2):246-263. PubMed ID: 30993586
[TBL] [Abstract][Full Text] [Related]
13. Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner.
Wu F; Lin Y; Cui P; Li H; Zhang L; Sun Z; Huang S; Li S; Huang S; Zhao Q; Liu Q
Cancer Chemother Pharmacol; 2018 Jun; 81(6):999-1006. PubMed ID: 29605876
[TBL] [Abstract][Full Text] [Related]
14. Metabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cells.
Ippolito L; Marini A; Cavallini L; Morandi A; Pietrovito L; Pintus G; Giannoni E; Schrader T; Puhr M; Chiarugi P; Taddei ML
Oncotarget; 2016 Sep; 7(38):61890-61904. PubMed ID: 27542265
[TBL] [Abstract][Full Text] [Related]
15. Acquisition of tumorigenic potential and therapeutic resistance in CD133+ subpopulation of prostate cancer cells exhibiting stem-cell like characteristics.
Kanwal R; Shukla S; Walker E; Gupta S
Cancer Lett; 2018 Aug; 430():25-33. PubMed ID: 29775627
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of biomarkers and their functions for docetaxel-resistant prostate cancer cells.
Deng L; Gu X; Zeng T; Xu F; Dong Z; Liu C; Chao H
Oncol Lett; 2019 Sep; 18(3):3236-3248. PubMed ID: 31452801
[TBL] [Abstract][Full Text] [Related]
17. CD44 Promotes Migration and Invasion of Docetaxel-Resistant Prostate Cancer Cells Likely via Induction of Hippo-Yap Signaling.
Lai CJ; Lin CY; Liao WY; Hour TC; Wang HD; Chuu CP
Cells; 2019 Mar; 8(4):. PubMed ID: 30935014
[TBL] [Abstract][Full Text] [Related]
18. Single-Cell Transcriptomics Analysis Identifies Nuclear Protein 1 as a Regulator of Docetaxel Resistance in Prostate Cancer Cells.
Schnepp PM; Shelley G; Dai J; Wakim N; Jiang H; Mizokami A; Keller ET
Mol Cancer Res; 2020 Sep; 18(9):1290-1301. PubMed ID: 32513898
[TBL] [Abstract][Full Text] [Related]
19. Extracellular vesicle mimics made from iPS cell-derived mesenchymal stem cells improve the treatment of metastatic prostate cancer.
Zhao Q; Hai B; Kelly J; Wu S; Liu F
Stem Cell Res Ther; 2021 Jan; 12(1):29. PubMed ID: 33413659
[TBL] [Abstract][Full Text] [Related]
20. Acetyl-11-keto-β-boswellic acid suppresses docetaxel-resistant prostate cancer cells in vitro and in vivo by blocking Akt and Stat3 signaling, thus suppressing chemoresistant stem cell-like properties.
Liu YQ; Wang SK; Xu QQ; Yuan HQ; Guo YX; Wang Q; Kong F; Lin ZM; Sun DQ; Wang RM; Lou HX
Acta Pharmacol Sin; 2019 May; 40(5):689-698. PubMed ID: 30171201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
